Viatris Inc. (VTRS)

Viatris continues to struggle with declining sales across all regions, with Q2-2025 net sales down 7% year over year. VTRS's Indore plant issues have significantly impacted results, but a full recover...

Investors closely monitor insider buys, as they can give hints surrounding the long-term picture.

VTRS beats on Q2 estimates with strength in branded drugs and growth in Greater China, lifting shares.

Viatris Inc. (NASDAQ:VTRS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Scott Andr...

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to...

Drugmaker Viatris beat Wall Street estimates for second-quarter profit and revenue on Thursday, helped by demand for its products in China, sending its shares up nearly 5% in early trading.

Viatris (VTRS) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.69 per share a year ago.

Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some o...

VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.

VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.